NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a lat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe. These are the products’ first global approvals. The medicines lower low-density lipoprotein cholesterol, or LDL-C, commonly called […]
NewAmsterdam Pharma has delivered a powerful long term share price gain, yet the recent pullback raises a sharper question for investors about how its current market value lines up with the company’s book value. With the stock now some distance below its earlier highs, the issue is whether the balance sheet still backs up where the price sits today. Over the past 3 years, NewAmsterdam Pharma has returned about 139%, which now puts real pressure on the numbers to show that book value keeps...
Detailed price information for Newamsterdam Pharma Company N.V. (NAMS-Q) from The Globe and Mail including charting and trades.
Detailed price information for Amgen Inc (AMGN-Q) from The Globe and Mail including charting and trades.
NewAmsterdam Pharma is rated a Hold and has seen a near 40% stock pullback post-Merck’s Lipfendra approval. Read more on NAMS stock here.
NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’
NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib de
This is the newest page. Registered accounts read further back.